AstraZeneca’s rare disease unit Alexion will acquire gene editing specialist LogicBio Therapeutics in a small buyout deal, the companies announced Monday.
Under the terms of the agreement, Alexion will acquire all of LogicBio’s outstanding shares for $2.07 each, representing a total deal value of about $68 million. The purchase price equates to a premium of more than 600% on LogicBio’s closing share price of $0.27 Friday.
